Skin Graft Template

Skin graft - identification of defect and donor site.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Defect site: Defect site
Defect size: Defect size
Donor site: Donor site
Indication: Indication/diagnosis
Radiographs/images: Radiographs/images reviewed/taken and findings

Consent: Consent/PARQ reviewed; signed/verbally obtained

Anesthesia: Anesthetic used
Carps: Carpules/amount

Surgical procedure support: Specific site/teeth, indication, and medical necessity
Operative details: Surgical access, tissue/bone removed or repositioned, closure materials
Image/specimen support: Radiographs/photos/specimen/lab as applicable

Procedure:
Recipient site prepared.
Donor site prepped.
Graft harvested.
Graft transferred to recipient site.
Graft secured with sutures.
Donor site closed/dressed.
Pressure dressing applied to graft.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
Avoid disturbing graft site.
Rx: Prescription or none

NV: Next visit

Documentation requirements

D7920 documentation does four things: prove the defect site exists and is large enough to require a skin graft, prove the donor site was harvested with consent and standard technique, prove the graft was inset and secured at the recipient site, and prove the donor site was closed and dressed appropriately. Because D7920 is by report, the operative narrative is the claim — there is no fee schedule shortcut. A defensible note includes:

• Defect site — explicit anatomy. Where the graft is going. "Anterior maxillary vestibule from canine to canine, ~3.5 cm anteroposterior x 1.2 cm vertical depth following vestibuloplasty (D7350)" beats "vestibule." Name the procedure that created the defect (vestibuloplasty, tumor excision, traumatic avulsion, scar revision) and link to its CDT code so the reviewer can see the parent procedure on the same claim.
• Defect size in square centimeters. Length x width or measured surface area. Carriers explicitly use defect size to bracket the by-report fee. "3.5 cm x 1.2 cm = 4.2 cm²" is concrete; "moderate-sized defect" is not. For irregular defects, document the largest two dimensions and the approximate total area.
• Donor site — explicit anatomy and laterality. "Left medial thigh, ~10 cm distal to the inguinal crease and 4 cm medial to the midline of the thigh" is the standard split-thickness skin graft donor site for intraoral reconstruction. Lateral thigh, buttock, and supraclavicular skin are reportable alternatives. Document the rationale for the donor site (concealment under clothing, scar acceptability to patient, surgeon preference). The donor site is a key audit element — auditors treat absent donor-site documentation as evidence the procedure was not actually a skin graft.
• Graft type — split-thickness vs full-thickness. Split-thickness skin graft (STSG) is the dominant choice for intraoral reconstruction — typically 0.012-0.018 inch thickness harvested with a powered or manual dermatome, leaving the donor-site dermis to re-epithelialize. Full-thickness skin graft (FTSG) is reserved for smaller defects where contraction must be minimized (e.g., perioral scar revision); the donor site is closed primarily. Document the thickness in inches or millimeters and the harvest instrument (e.g., "Padgett dermatome set at 0.015 inches" or "elliptical full-thickness excision, primary closure").
• Indication / diagnosis — why a skin graft over a mucosal substitute. The single most-reviewed element on a D7920 claim. The reportable indications are: (a) defect too large for a palatal or tuberosity mucosal graft — palatal donor-site capacity is bounded by the greater palatine artery anatomy, typically <3 cm² of usable graft; (b) vestibuloplasty with planned prosthesis where keratinized, prosthesis-tolerant surface is required and an adjacent mucosal donor is unavailable or already harvested; (c) post-tumor reconstruction where the defect is contiguous with the resection bed and an autogenous mucosal graft is anatomically infeasible; (d) traumatic or burn defect with no viable adjacent donor mucosa; (e) revision of failed mucosal graft where re-grafting from the same intraoral donor is not possible. State which indication applies and why the alternative was not chosen.
• Radiographs / images / pre-op photo. Pre-op intraoral photograph of the defect (or the planned defect site at the time of the parent procedure) is functionally required for a clean by-report claim. Pre-op photo of the donor site marked for harvest is good practice for OMFS records but not always submitted with the claim. Post-op photos of recipient and donor sites at suture removal close the documentation loop.
• Medical and dental history. Reviewed today; flag bleeding diatheses, anticoagulants and antiplatelet therapy (donor-site bleeding is a meaningful issue with STSG), uncontrolled diabetes (graft-take is impaired), tobacco use (significantly impairs graft-take and is the single strongest patient-side predictor of graft loss), prior radiation to the recipient site, immunosuppression, history of keloid or hypertrophic scarring (relevant for donor-site cosmesis), and any history of prior skin grafts or donor-site harvests. The risk-factor profile drives the consent discussion.
• Vitals and ASA classification. Pre-op BP and pulse; ASA classification (I-IV) routinely documented for OMFS surgical visits and required for sedation billing.
• Informed consent / PARQ. Risks specific to D7920: donor-site pain (often disproportionate to the recipient-site pain in patient surveys, especially first 7-10 days), donor-site delayed re-epithelialization or hypertrophic scarring (especially in tobacco users, diabetics, and patients with darker pigmented skin), recipient-site graft loss (partial or complete) requiring re-grafting, infection at either site, contracture of the graft over time (greater for STSG than FTSG, relevant when grafting near vermilion or oral commissure), color and texture mismatch between skin and surrounding mucosa, hair growth from the graft (when harvested from hair-bearing skin — counsel on choice of donor site), and the longer healing timeline (3-6 weeks recipient, 2-3 weeks donor) compared with mucosal grafts. Note signed surgical consent at consult plus verbal re-consent today.
• Anesthesia. Agent, concentration, vasoconstrictor, and technique for both donor and recipient sites. Donor-site anesthesia is typically tumescent local infiltration (lidocaine 0.5% with epinephrine 1:200,000-1:400,000, large volume); recipient-site anesthesia matches the parent procedure (regional blocks, supplemental infiltration). When done under IV moderate sedation (D9243) or general anesthesia (hospital-based, billed under medical), document the sedation code separately. D7920 is more frequently performed under sedation than most pre-prosthetic codes because of donor-site discomfort and operative time.
• Operative narrative — donor-site harvest. The detail that drives the by-report fee. Explicit description of: donor-site preparation (chlorhexidine or povidone-iodine prep, sterile drape, marking the harvest area to dimension), tumescent infiltration when used, dermatome setting and pass count (e.g., "Padgett electric dermatome set at 0.015 inches; two passes harvested a graft of approximately 4 cm x 2 cm"), graft handling (saline-moistened gauze, mesh expansion when used — typically not for intraoral reconstruction because of bolus contact), and donor-site hemostasis (epinephrine-soaked gauze, electrocautery for bleeders). Note the harvest dimensions explicitly because the carrier will compare them to the defect size.
• Operative narrative — recipient-site preparation and graft inset. Recipient-site bed preparation (debridement of granulation tissue, hemostasis, pulse-lavage irrigation when applicable), graft trimming to defect dimensions, graft orientation (epidermal side out for intraoral skin grafts), graft fixation (interrupted resorbable suture around the perimeter, quilting sutures across the bed to prevent shear and seroma, tie-over bolster dressing or stent for vestibuloplasty cases), and confirmation of complete graft-bed contact without lift-off.
• Donor-site closure and dressing. STSG donor sites are not closed primarily — they re-epithelialize from residual dermal adnexa over 14-21 days. Standard dressings: petrolatum gauze (Xeroform, Adaptic), semi-occlusive film (Tegaderm, OpSite), foam dressing (Mepilex), or hydrocolloid. Document the dressing chosen and the planned dressing-change schedule (often once at 7 days, then re-evaluation). FTSG donor sites are closed primarily with layered suture and a standard pressure dressing. Document the closure and dressing for both donor and recipient sites.
• Tie-over bolster or stent. A tie-over bolster (Xeroform packed under crossed long-tail sutures) or a pre-fabricated acrylic stent (vestibuloplasty cases — impressioned at the consult and delivered the day of surgery) maintains pressure on the graft for 5-7 days, prevents shear, and minimizes hematoma under the graft. Document the bolster or stent and the planned removal milestone. Auditors view absence of bolster / stent documentation as evidence the graft was not adequately secured.
• Surgical image support. Intraoperative photo of the harvested graft on the back table, the prepared recipient bed, the inset graft, and the bolster / stent are increasingly expected on by-report claims. Photo of the donor-site dressing in place closes the donor-site loop. Label each photo with patient identifier, date, and view.
• Specimen. Skin graft is generally not submitted to pathology when the donor site is healthy and the harvest is uncomplicated. Submit when the donor site has incidental pathology (atypical pigmented lesion, suspicious nevus) requiring excision rather than dermatome harvest — in which case the specimen is sent for histopathologic evaluation.
• Hemostasis. Achieved at both sites. Donor-site bleeding from a freshly dermatomed surface can be brisk and is often managed with epinephrine-soaked gauze under pressure, electrocautery for individual bleeders, and the dressing itself. Recipient-site bleeding is managed with the parent-procedure technique. Document explicitly given the procedure's bleeding potential at two sites.
• Complications. Explicit "None" or describe (donor-site oversize harvest with primary closure conversion; intraoperative hypotension; partial graft loss noted at inset due to inadequate bed; greater-than-expected donor-site bleeding requiring extended pressure dressing; allergic reaction to dressing material).
• Patient tolerance / response. Tolerated well, vitals stable, no adverse events; ambulatory dismissal with escort if sedated; donor-site pain assessment before discharge.
• Post-op instructions. Recipient site: soft / pureed diet 7-14 days, no removable prosthesis x 3-6 weeks (or as instructed for the specific reconstruction), gentle salt-water rinses starting 24 h post-op, do not disturb the bolster / stent, return precautions (bolster dislodgement, exposed graft, foul taste, fever, uncontrolled bleeding). Donor site: keep dressing intact and dry until first dressing change at 5-7 days, no soaking or submerging the donor site x 14 days, limit activity that stretches the donor area for 7-10 days, expect oozing of serosanguinous fluid through the dressing for the first 48-72 h, return precautions for donor-site pain disproportionate to expected, dressing saturation, fever, or signs of infection. Provide written instructions for both sites; document verbal review.
• Prescriptions. Analgesic regimen (ibuprofen 600 mg q6h plus alternating acetaminophen as first-line per ADA / AAOMS NSAID-first guidance; a short opioid course — hydrocodone-acetaminophen 5/325 q6h x 2-3 days — is more frequently appropriate for D7920 than for most pre-prosthetic codes because of donor-site pain, per practice protocol and state PMP rules); antibiotic per indication (no routine prophylaxis indicated for healthy patients per AAOMS guidelines, but many surgeons use a 5-7 day course of amoxicillin 500 mg TID or clindamycin 300 mg QID given the two-site exposure and the bolster occlusion of the recipient bed; document indication and counseling); chlorhexidine 0.12% rinse BID for plaque control around an intraoral bolster; topical antibiotic ointment (bacitracin or mupirocin) at the donor-site dressing margins per practice protocol. Document drug, dose, route, frequency, duration, and counseling.
• Next visit. Recipient-site bolster / stent removal at 5-7 days; recipient-site graft assessment at 2 weeks and 4 weeks; donor-site dressing change at 5-7 days, dressing removal at 14-21 days when re-epithelialization is complete; prosthetic milestone (final impression appointment) typically 6-12 weeks post-op once graft contour is stable. Schedule both sites separately and document the timeline.
• Provider signature and any auxiliary operator initials.

Two phrases that defuse the most common audit questions on D7920: explicit donor-site anatomy with dimensions and an explicit rationale for skin over an intraoral mucosal substitute. Both track the published carrier review criteria for by-report skin graft claims.

Common denial reasons

D7920 is a by-report code with meaningful audit exposure because the fee, the indication, and the procedural detail are all on the surgeon to justify. The most frequent reasons it is denied, downgraded, or recouped:

• Operative report not attached to the claim — the dominant denial. By-report codes are unprocessable without an operative narrative; carriers will deny "insufficient documentation" rather than request records. Always attach the op report (or paste the chart note into the claim narrative field) on first submission.
• Missing donor-site anatomy and dimensions — auditors treat absent donor-site documentation as evidence the procedure was not actually a skin graft. "Skin graft to vestibule" without a donor-site location, harvest dimensions, or harvest technique is functionally a denial.
• Missing defect size — defect size in cm² is the carrier's anchor for the by-report fee. "Moderate defect" is not a measurement.
• No rationale for skin over mucosal substitute — when the chart fails to explain why a skin graft was chosen over a palatal mucosal graft, acellular dermal matrix, or allogeneic dermis, carriers downgrade to the mucosal-graft fee or deny as not medically necessary.
• No parent procedure on the claim — D7920 in isolation, without a vestibuloplasty (D7350), tumor excision (D7440 / D7441 / D7450 / D7460), or trauma reconstruction code, looks like a stand-alone graft with no defect to cover. Bill D7920 alongside the parent procedure or with the parent procedure on recent claim history.
• Coded as D7920 but actually a mucosal graft — palatal, tuberosity, or attached gingival mucosa harvested and grafted is not skin. Carrier re-codes to D4271 / D4273 / D4275 / D4277 and pays at the lower allowable, or denies for code mismatch.
• No bolster / stent / fixation documentation — auditors view absence of bolster or stent documentation as evidence the graft was not adequately secured, which weakens medical-necessity argument and the by-report fee.
• No pre-op or intraoperative photographs — by-report claims are increasingly expected to include photo evidence of the defect and the inset graft. Absence is a common downgrade trigger.
• Default-template chart note — identical D7920 narrative across patients with no patient-specific dimensions, donor sites, or indications. Medicaid MCO recoupment programs flag template-fingerprint patterns.
• Tobacco user with no counseling documentation — when the graft fails and re-grafting is requested, carriers commonly deny the second D7920 if the original chart did not document tobacco-cessation counseling and risk acknowledgment.
• Fee out of line with carrier benchmark — carriers benchmark D7920 against CPT 15120 / 15240 Medicare allowable. Fees significantly above benchmark trigger downgrade rather than full payment; submit the proposed fee with rationale (operative time, donor-site complexity, patient-specific factors) on pre-determination.
• Operator signature / initials missing — auto-flagged by automated audit systems.
• Hospital-based free-flap reconstruction billed as D7920 — D7920 is the dental-claim analog and is generally inadequate for radial forearm, fibular, anterolateral thigh, or pectoralis major free flaps. Those are CPT-coded under medical and bundled into the hospital surgical fee.